VolitionRX Limited (NYSEAMERICAN:VNRX) Sees Significant Decrease in Short Interest

VolitionRX Limited (NYSEAMERICAN:VNRX) was the recipient of a significant decline in short interest during the month of September. As of September 15th, there was short interest totaling 1,004,963 shares, a decline of 54.8% from the August 31st total of 2,224,050 shares. Approximately 7.9% of the shares of the company are sold short. Based on an average daily trading volume, of 1,733,578 shares, the days-to-cover ratio is presently 0.6 days.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. Benchmark reaffirmed a “hold” rating on shares of VolitionRX in a research report on Monday, August 17th. Maxim Group reissued a “buy” rating and set a $4.00 target price on shares of VolitionRX in a report on Thursday, June 18th. Two investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $28.00.

VolitionRX Stock Down 2.4%

Shares of VNRX traded down $0.01 during trading hours on Monday, hitting $0.25. The company had a trading volume of 905,955 shares, compared to its average volume of 3,126,849. The business has a fifty day moving average of $0.55 and a 200-day moving average of $1.83. The firm has a market cap of $3.45 million, a price-to-earnings ratio of -0.07 and a beta of 1.10. VolitionRX has a 12 month low of $0.23 and a 12 month high of $14.80.

VolitionRX (NYSEAMERICAN:VNRX) last announced its earnings results on Thursday, August 13th. The medical research company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.28). The company had revenue of $0.40 million for the quarter, compared to analyst estimates of $0.41 million. On average, equities analysts expect that VolitionRX will post -1.88 EPS for the current fiscal year.

VolitionRX Company Profile

VolitionRx Limited is a life sciences company developing blood-based diagnostic tests for cancer and other diseases. The company’s technology is based on nucleosomes, fragments of DNA and associated proteins released into the bloodstream during cell death, which may provide information useful for disease detection, monitoring and treatment decisions.

VolitionRx’s product development activities include its Nu.Q technology platform and Nu.Q Vet, a suite of veterinary cancer screening and monitoring tests designed for use in dogs and other companion animals.